Nuvectis Pharma (NVCT) Net Equity Issued and Repurchased (2021 - 2026)

Nuvectis Pharma (NVCT) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $7000.0 in Q1 2026.

• For the quarter ending Q1 2026, Net Equity Issued and Repurchased fell 99.45% year-over-year to $7000.0; the trailing twelve-month figure through Mar 2026 stood at $14.3 million (up 69.5% YoY), and the FY2025 full-year result was $15.7 million, up 30.44% from the prior year.
• Net Equity Issued and Repurchased fell to $7000.0 in Q1 2026, from $175000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $13.5 million in Q3 2025 to a low of $7000.0 in Q1 2026.
• A 4-year average of $2.7 million and a median of $1.3 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased surged 800.0% in 2025 and tumbled 99.45% in 2026, its largest moves.
• Tracing NVCT's Net Equity Issued and Repurchased over 4 years: stood at $901000.0 in 2023, then soared by 338.73% to $4.0 million in 2024, then plunged by 95.57% to $175000.0 in 2025, then sank by 96.0% to $7000.0 in 2026.
• Business Quant data shows NVCT's Net Equity Issued and Repurchased at $7000.0 in Q1 2026, $175000.0 in Q4 2025, and $13.5 million in Q3 2025.